Xeris Biopharma (NASDAQ:XERS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Thursday.
Several other brokerages have also issued reports on XERS. Leerink Partners increased their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum raised their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, Oppenheimer raised their target price on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $6.25.
Check Out Our Latest Stock Report on Xeris Biopharma
Xeris Biopharma Stock Performance
Shares of XERS stock traded up $0.02 on Thursday, reaching $4.85. 444,739 shares of the company's stock traded hands, compared to its average volume of 1,960,705. Xeris Biopharma has a 12-month low of $1.86 and a 12-month high of $6.07. The business's 50 day moving average price is $4.72 and its two-hundred day moving average price is $3.98. The company has a market capitalization of $757.69 million, a P/E ratio of -10.74 and a beta of 1.10.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million. Research analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.
Insider Buying and Selling at Xeris Biopharma
In other news, insider Beth Hecht sold 40,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares of the company's stock, valued at approximately $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.47% of the company's stock.
Institutional Investors Weigh In On Xeris Biopharma
Hedge funds and other institutional investors have recently made changes to their positions in the business. Legato Capital Management LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at about $482,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Xeris Biopharma by 106.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock valued at $581,000 after purchasing an additional 88,224 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Xeris Biopharma by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company's stock valued at $26,778,000 after purchasing an additional 133,738 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Xeris Biopharma by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company's stock valued at $384,000 after purchasing an additional 10,748 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Xeris Biopharma by 20.8% in the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company's stock valued at $1,117,000 after purchasing an additional 67,557 shares during the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
